drugset
drugset / Trial / NCT05101317

A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain

NCT05101317 ↗

Phase 2 Completed 142 enrolled Hope Medicine (Nanjing) Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.

Timeline

Start
2021-10-11
Primary completion
2024-09-26
Completion
2025-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject HMI-115 Monoclonal antibody 60 mg Subcutaneous
Subject HMI-115 Monoclonal antibody 120 mg Subcutaneous
Subject HMI-115 Monoclonal antibody 240 mg Subcutaneous

Indications

endometriosis